An interventional study of L-arginine 1000 mg and Acetylesalicylic acid75mg and acetylsalicylic acid 75 mg in Intrauterine Growth Restriction Asymmetrical, sponsored by Ain Shams University. Status unknown at 1 site in Egypt. Open to female participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-14.
Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Fetal Growth Retardation with a site in Egypt — 1 open to participants now, 1 under way, none of them phase 3. Fetal Growth Retardation · Egypt.
Among the 22 studies in Fetal Growth Retardation with a site in Egypt, this one has the largest planned enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2017, is one of 3 with no phase, and was the 12th registered.
262 studies on the registry are indexed under Fetal Growth Retardation; 69 are open to participants now.
Browse Fetal Growth Retardation studies →1 of the 22 studies in Fetal Growth Retardation with a site in Egypt is open now. Recruiting first, the newest first:
Assiut University · Sites in Egypt
Women only · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 48 Fetal Growth Retardation studies recruiting now, 24 (50%) set no upper age limit and 21 (44%) stop at 75 or younger; 16 take children under 18; 24 take healthy volunteers.
This study: 20 Years to 40 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 260 is above the median of 150 across 110 interventional studies indexed under Fetal Growth Retardation.
Median enrollment 90 across the 11 interventional studies, 100 across the 11 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 22 has an industry lead sponsor. The 9 most frequent:
Ain Shams University is the lead sponsor of 1,954 studies on the registry; 430 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Ain Shams University has 5 studies filed under Fetal Growth Retardation — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Fetal Growth Retardation with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Intrauterine growth restriction is an important problem in neonatal care. Intrauterine growth restriction (IUGR) is defined as a fetal weight below the 10th percentile for gestational age. One of the main causes of IUGR is placental insufficiency.
Nitric oxide(NO) increases placental blood flow. So,it might be useful to improve IUGR pregnancy outcome .
The study population includes pregnant women attending Antenatal care clinic of Ain Shams University Maternity Hospital who first time diagnosed of IUGR at our antenatal care outpatient clinic either referred for this cause After confirm diagnosis of IUGR and distributing patient into two groups Patient in first group will receive oral L-arginine 3000mg/day till delivery and Acetylesalicylic acid 75mg once daily.
Patients in second group will receive Acetylesalicylic acid 75mg once daily. then follow up of both group by:
A) Head circumference, Abdominal circumference, femur length B) Fetal weight C) Liquor amount: Amniotic Fluid Index Or MeanVertical Pocket
Decision of delivery will be determined when:
A) Fetal distress (non stress CTG) B) Mother starts labour C) Reversed umbilical artery Doppler.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
L-arginine 1000mg capsules( manufactured by Putriant Pride,INC Holbrook,NY 11741 U.S.A.) every 8 hours Acetylesalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) once daily will be given for patients of group A starting from diagnosis till birth
Drug: L-arginine 1000 mg and Acetylesalicylic acid75mg
acetylsalicylic acid 75 mg tablet(manufactured by Multi_Apex Pharma , Egypt) orally once daily will be given for patients of group B starting from diagnosis till birth
Drug: acetylsalicylic acid 75 mg
Drug page: Arginine
l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
Also known as: L- arginine 1000mg capsule and Ezacard 75 mg tablet
acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
Also known as: Ezacard 75mg
Birth weight
neonatal birth weight will be measured immediately following delivery and compared with the estimated fetal weight measured by ultrasound
Time frame: 15 min
Apgar score
The Apgar scale is determined by evaluating the newborn baby on five simple criteria on a scale from zero to two, then summing up the five values thus obtained. The resulting Apgar score ranges from zero to 10. The five criteria are (Appearance, Pulse, Grimace, Activity, Respiration).
Time frame: at one and five minute after birth.
Amniotic fluid index
Amniotic fluid index (sum of the vertical diameter of the four pocket of amniotic fluid )
Time frame: evey one week from 28 weeks gestation till 40 weeks gestation
Umbilical artery Doppler
umbilical artery Doppler will measured by two dimensional ultrasound power Doppler twice weekly for the presence of any abnormality as: marked decreased diastolic blood flow, absent or reversed diastolic blood flow.
Time frame: every from 28 weeks gestation till 40 weeks gestation
Started Oct 2017 (actual). Primary completion is estimated for Dec 2018, 13 months after the start.
Of 39 non-industry interventional studies with no phase under Fetal Growth Retardation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 52. This study's planned 13 months is below that.
Counting every sponsor, half of 40 studies reached it within 35 months; a quarter within 18 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Arginine